Role of reactive oxygen species in p53 activation during cisplatin-induced apoptosis of rat mesangial cells

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 8, 2014, Pages 1135-1141

  Ju, S M ^a   Pae, H O ^b   Kim, W S ^a   Kang, D G ^c   Lee, H S ^c   Jeon, B H ^a  

^a Wonkwang University   (South Korea)

^b Wonkwang University School of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

Cisplatin; Nephrotoxicity; P53; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; CISPLATIN; DIMETHYLTHIOUREA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PIFITHRIN ALPHA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASP3 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUOROMETRY; INCUBATION TIME; MESANGIUM CELL; MTT ASSAY; NEPHROTOXICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CASPASE 3; CELL LINE; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MESANGIAL CELLS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902190729     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BARABAS K, MILNER R, LURIE D, ADIN C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008; 6: 1-18.
2. HANIGAN MH, DEVARAJAN P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003; 1: 47-61.
3. MCWHINNEY SR, GOLDBERG RM, MCLEOD HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
4. RYBAK LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 364-369. (Pubitemid 47373985)
5. CUBEDDU LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992; 19: 2-13. (Pubitemid 23047122)
6. KINTZEL PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
7. PABLA N, DONG Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007. (Pubitemid 351543900)
8. JIN Z, EL-DEIRY WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4: 139-163. (Pubitemid 41351311)
9. DECKER P, MULLER S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 2002; 3: 275-283. (Pubitemid 34823021)
10. ARANY I, SAFIRSTEIN RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464. (Pubitemid 37176691)
11. JIANG M, DONG Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008; 327: 300-307.
12. GALLUZZI L, SENOVILLA L, VITALE I, MICHELS J, MARTINS I, KEPP O, CASTEDO M, KROEMER G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-1883.
13. CASARES C, RAMÍREZ-CAMACHO R, TRINIDAD A, ROLDÁN A, JORGE E, GARCÍA-BERROCAL JR. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol 2012; 269: 2455-2459.
14. CONKLIN KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18. (Pubitemid 30650661)
15. SAHIN K, SAHIN N, KUCUK O. Lycopene and chemotherapy toxicity. Nutr Cancer 2010; 62: 988-995.
16. MAILLET A, PERVAIZ S. Redox regulation of p53, redox effectors regulated by p53: a subtle balance. Antioxid Redox Signal 2012; 16: 1285-1294.
17. LIU B, CHEN Y, ST CLAIR DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008; 44: 1529-1535.
18. UEDA S, MASUTANI H, NAKAMURA H, TANAKA T, UENO M, YODOI J. Redox control of cell death. Antioxid Redox Signal 2002; 4: 405-414. (Pubitemid 34753380)
19. VAUGHAN AT, BETTI CJ, VILLALOBOS MJ. Surviving apoptosis. Apoptosis 2002; 7: 173-177. (Pubitemid 34273133)
20. YAO X, PANICHPISAL K, KURTZMAN N, NUGENT K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124. (Pubitemid 47262919)
21. SEDLETSKA Y, GIRAUD-PANIS MJ, MALINGE JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251-265. (Pubitemid 40655276)
22. HEANEY ML, GARDNER JR, KARASAVVAS N, GOLDE DW, SCHEINBERG DA, SMITH EA, O'CONNOR OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008; 68: 8031-8038.
23. JIANG M, WEI Q, PABLA N, DONG G, WANG CY, YANG T, SMITH SB, DONG Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007; 73: 1499-1510. (Pubitemid 46452592)
24. KANE DJ, SARAFIAN TA, ANTON R, HAHN H, GRALLA EB, VALENTINE JS, ORD T, BREDESEN DE. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-1277. (Pubitemid 24036095)
25. HARRIS SL, LEVINE AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908. (Pubitemid 40638098)
26. SCHULER M, GREEN DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684-688. (Pubitemid 33131760)